Blastomycosis

Patients should be instructed to monitor for medication-related side effects, particularly the development of signs or symptoms of hepatotoxicity such as jaundice or stool color changes associated with azole antifungal therapy.

Women of childbearing age on azole therapy should be cautioned to avoid becoming pregnant during this therapy. Patients should be questioned about the possibility of pregnancy.

Patients should be evaluated in follow-up initially on a monthly basis and then every 3 months until resolution of disease and discontinuation of antifungal therapy.

Centers for Disease Control and Prevention: fungal diseases - blastomycosis Opens in new window